175 related articles for article (PubMed ID: 35928802)
1. HS-1793 inhibits cell proliferation in lung cancer by interfering with the interaction between p53 and MDM2.
Lim C; Lee PCW; Shim S; Jang SW
Oncol Lett; 2022 Aug; 24(2):290. PubMed ID: 35928802
[TBL] [Abstract][Full Text] [Related]
2. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction.
Fortunato O; Boeri M; Moro M; Verri C; Mensah M; Conte D; Caleca L; Roz L; Pastorino U; Sozzi G
Cell Death Dis; 2014 Dec; 5(12):e1564. PubMed ID: 25501825
[TBL] [Abstract][Full Text] [Related]
3. L-GILZ binds p53 and MDM2 and suppresses tumor growth through p53 activation in human cancer cells.
Ayroldi E; Petrillo MG; Bastianelli A; Marchetti MC; Ronchetti S; Nocentini G; Ricciotti L; Cannarile L; Riccardi C
Cell Death Differ; 2015 Jan; 22(1):118-30. PubMed ID: 25168242
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-340 inhibits prostate cancer cell proliferation and metastasis by targeting the MDM2-p53 pathway.
Huang K; Tang Y; He L; Dai Y
Oncol Rep; 2016 Feb; 35(2):887-95. PubMed ID: 26718483
[TBL] [Abstract][Full Text] [Related]
5. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.
Shangary S; Ding K; Qiu S; Nikolovska-Coleska Z; Bauer JA; Liu M; Wang G; Lu Y; McEachern D; Bernard D; Bradford CR; Carey TE; Wang S
Mol Cancer Ther; 2008 Jun; 7(6):1533-42. PubMed ID: 18566224
[TBL] [Abstract][Full Text] [Related]
6. Slug promotes p53 and p21 protein degradation by inducing Mdm2 expression in HCT116 colon cancer cells.
Kim J; Lee J; Kim U; Park JK; Um HD
Oncol Lett; 2021 Sep; 22(3):681. PubMed ID: 34345306
[TBL] [Abstract][Full Text] [Related]
7. Emerging Role of MDM2 as Target for Anti-Cancer Therapy: A Review.
Shaikh MF; Morano WF; Lee J; Gleeson E; Babcock BD; Michl J; Sarafraz-Yazdi E; Pincus MR; Bowne WB
Ann Clin Lab Sci; 2016 Dec; 46(6):627-634. PubMed ID: 27993876
[TBL] [Abstract][Full Text] [Related]
8. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B
Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266
[TBL] [Abstract][Full Text] [Related]
9. Ras homolog gene family, member A promotes p53 degradation and vascular endothelial growth factor-dependent angiogenesis through an interaction with murine double minute 2 under hypoxic conditions.
Ma J; Xue Y; Cui W; Li Y; Zhao Q; Ye W; Zheng J; Cheng Y; Ma Y; Li S; Han T; Miao L; Yao L; Zhang J; Liu W
Cancer; 2012 Sep; 118(17):4105-16. PubMed ID: 22907703
[TBL] [Abstract][Full Text] [Related]
10. Bibenzyl analogue DS-1 inhibits MDM2-mediated p53 degradation and sensitizes apoptosis in lung cancer cells.
Putri HE; Nutho B; Rungrotmongkol T; Sritularak B; Vinayanuwattikun C; Chanvorachote P
Phytomedicine; 2021 May; 85():153534. PubMed ID: 33773191
[TBL] [Abstract][Full Text] [Related]
11. Activation of lung p53 by Nutlin-3a prevents and reverses experimental pulmonary hypertension.
Mouraret N; Marcos E; Abid S; Gary-Bobo G; Saker M; Houssaini A; Dubois-Rande JL; Boyer L; Boczkowski J; Derumeaux G; Amsellem V; Adnot S
Circulation; 2013 Apr; 127(16):1664-76. PubMed ID: 23513067
[TBL] [Abstract][Full Text] [Related]
12. The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1.
Reuther C; Heinzle V; Nölting S; Herterich S; Hahner S; Halilovic E; Jeay S; Wuerthner JU; Aristizabal Prada ET; Spöttl G; Maurer J; Auernhammer CJ
Neuroendocrinology; 2018; 106(1):1-19. PubMed ID: 27871087
[TBL] [Abstract][Full Text] [Related]
13. Epithelial cell-derived periostin functions as a tumor suppressor in gastric cancer through stabilizing p53 and E-cadherin proteins via the Rb/E2F1/p14ARF/Mdm2 signaling pathway.
Lv H; Liu R; Fu J; Yang Q; Shi J; Chen P; Ji M; Shi B; Hou P
Cell Cycle; 2014; 13(18):2962-74. PubMed ID: 25486483
[TBL] [Abstract][Full Text] [Related]
14. Metallothionein 1M (MT1M) inhibits lung adenocarcinoma cell viability, migration, and expression of cell mobility-related proteins through MDM2/p53/MT1M signaling.
Xu W; Jiang GJ; Shi GZ; Chen MZ; Ma TL; Tan YF
Transl Cancer Res; 2020 Apr; 9(4):2710-2720. PubMed ID: 35117630
[TBL] [Abstract][Full Text] [Related]
15. Silencing Ribosomal Protein L22 Promotes Proliferation and Migration, and Inhibits Apoptosis of Gastric Cancer Cells by Regulating the Murine Double Minute 2-Protein 53 (MDM2-p53) Signaling Pathway.
Sun Z; Qiu Z; Wang Z; Chi H; Shan P
Med Sci Monit; 2021 May; 27():e928375. PubMed ID: 34050122
[TBL] [Abstract][Full Text] [Related]
16. Long non‑coding RNA PCAT6 promotes the development of osteosarcoma by increasing MDM2 expression.
Guan X; Xu Y; Zheng J
Oncol Rep; 2020 Dec; 44(6):2465-2474. PubMed ID: 33125146
[TBL] [Abstract][Full Text] [Related]
17. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
18. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
[TBL] [Abstract][Full Text] [Related]
19. Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis.
Lou J; Hao Y; Lin K; Lyu Y; Chen M; Wang H; Zou D; Jiang X; Wang R; Jin D; Lam EW; Shao S; Liu Q; Yan J; Wang X; Chen P; Zhang B; Jin B
Mol Cancer; 2020 Sep; 19(1):138. PubMed ID: 32894144
[TBL] [Abstract][Full Text] [Related]
20. Enhanced G1 arrest and apoptosis via MDM4/MDM2 double knockdown and MEK inhibition in wild-type
Wang X; Yamamoto Y; Imanishi M; Zhang X; Sato M; Sugaya A; Hirose M; Endo S; Natori Y; Moriwaki T; Yamato K; Hyodo I
Oncol Lett; 2021 Jul; 22(1):558. PubMed ID: 34084225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
